Invex Therapeutics Ltd has released a press release.
Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Invex Therapeutics Ltd. on 6ix
Story so far
Earlier from Invex Therapeutics
- 4E and Annual Report to shareholders
- Invex receives IND approval
- Quarterly Activities/Appendix 4C Cash Flow Report
- HREC and TGA Approval to Commence Phase 3 in Australia
- Invex Receives UK Approval to Commence Phase III Trial
Later from Invex Therapeutics
- First Australian Site Activated in IIH EVOLVE Phase 3
- First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
- Invex Receives $0.46 Million R&D Tax Rebate
- First Patient Randomised in IIH EVOLVE Phase III Trial
- MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics